Given the resulting glutamine addiction of cancer cells, the development of allosteric small molecule inhibitors that target glutaminase activity is being examined as a potential therapeutic strategy to block tumor progression in various malignancies including aggressive breast, lung, and pancreatic cancers, as well as for their effectiveness when combined with other anti-cancer drugs11–16. The gene discussed is GLS; the disease is cancer.